| __timestamp | Ligand Pharmaceuticals Incorporated | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 9136000 | 25434000 |
| Thursday, January 1, 2015 | 5807000 | 23783000 |
| Friday, January 1, 2016 | 5571000 | 29763000 |
| Sunday, January 1, 2017 | 5366000 | 12065000 |
| Monday, January 1, 2018 | 6337000 | 5508000 |
| Tuesday, January 1, 2019 | 11347000 | 75173000 |
| Wednesday, January 1, 2020 | 30419000 | 81497000 |
| Friday, January 1, 2021 | 62176000 | 85731000 |
| Saturday, January 1, 2022 | 52827000 | 63572000 |
| Sunday, January 1, 2023 | 35049000 | 54922000 |
| Monday, January 1, 2024 | 41070000 |
Unveiling the hidden dimensions of data
In the ever-evolving world of biotechnology, understanding cost dynamics is crucial. Ligand Pharmaceuticals Incorporated and Mesoblast Limited, two prominent players, have shown intriguing trends in their cost of revenue from 2014 to 2023. Ligand Pharmaceuticals saw a significant increase, peaking in 2021 with a cost of revenue nearly 11 times higher than in 2014. However, by 2023, this figure had decreased by approximately 44%. Meanwhile, Mesoblast Limited experienced a more volatile journey, with costs peaking in 2021, marking a 237% increase from 2014. Despite a subsequent decline, their 2023 costs remained over double those of 2014. These trends highlight the dynamic nature of the biotech industry, where strategic investments and market conditions can dramatically influence financial outcomes. Missing data for 2024 suggests ongoing developments, leaving room for future analysis.
Cost of Revenue: Key Insights for Eli Lilly and Company and Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Ligand Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc. vs Mesoblast Limited: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down GSK plc and Mesoblast Limited's Expenses
Cost of Revenue: Key Insights for Biogen Inc. and Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Mesoblast Limited
Analyzing Cost of Revenue: Cytokinetics, Incorporated and Mesoblast Limited
Cost of Revenue Trends: Vericel Corporation vs Ligand Pharmaceuticals Incorporated
Cost Insights: Breaking Down Ligand Pharmaceuticals Incorporated and MiMedx Group, Inc.'s Expenses
Analyzing Cost of Revenue: Mesoblast Limited and Taro Pharmaceutical Industries Ltd.